COMP <GO>
HCAT vs AAPL // EV/EBITDA & P/E VALUATION
Health Catalyst Inc (NASDAQ) VS. Apple Inc. (NASDAQ) • 15-METRIC TALLY: HCAT 0
— AAPL 10
■ METRIC PARITY
LAST: $1.79 (-0.56%) • MKT CAP: $134.7M
valuation
—
LAST: $348.91 (+1.48%) • MKT CAP: $5.09T
valuation
30.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HCAT VS. AAPL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HCAT | AAPL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 48.65% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 81.38% | -116.38 | AAPL | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 30.1x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.18% | 2.72% | -2.90 | AAPL | /fcf-yield <GO> |
| Operating Margin | -51.70% | 33.17% | -84.87 | AAPL | /operating-margins <GO> |
| Net Profit Margin | -57.20% | 27.62% | -84.82 | AAPL | /net-margins <GO> |
| Revenue Growth (YoY) | 1.50% | 14.24% | -12.74 | AAPL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.31% | -0.31 | AAPL | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 13.54 | -13.34 | AAPL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 9/9 | -5.00 | AAPL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 5.76% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.8 | 66.6 | -19.84 | AAPL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.14 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 35.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $134.7M | $5.09T | -$5.09T | AAPL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HCAT REV | AAPL REV | HCAT GROSS % | AAPL GROSS % | HCAT FCF | AAPL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $311.1M | $416.16B | — | 46.9% | -$237.0K | $98.77B |
| FY 2024 | $306.6M | $391.04B | — | 46.2% | $12.9M | $108.81B |
| FY 2023 | $295.9M | $383.29B | — | 44.1% | -$33.1M | $99.58B |
| FY 2022 | — | $394.33B | — | 43.3% | — | $111.44B |
| FY 2021 | — | $365.82B | — | 41.8% | — | $92.95B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HCAT // BETA —
AAPL // BETA 1.14